Why Is Hims & Hers Health ( $HIMS) Stock Up +4.22% Today? HIMS rose +4.22% to about $30.59 during regular New York trading, extending a two-session rebound. The advance followed European Union approval of Novo Nordisk's daily oral Wegovy for weight management. Investors treated the approval as a positive read-through for the broader obesity-treatment market, lifting weight-loss-focused names including HIMS. The gain came despite the approval belonging to a competitor, underscoring broad GLP-1 sector momentum. Traders are watching HIMS's shift toward branded GLP-1 products and its next earnings report for confirmation of the trend.